Centers | ||
|
|
|
EU-OPENSCREEN | test | Therapeutic Accelerator Program (TAP) |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
sfgd |
Test |
Partnerships |
Events |
Jobs |
GSK and MD Anderson to co-develop new cancer therapeuticsGlaxoSmithkline and MD Anderson Cancer Center entered into a co-development and license agreement to develop antibody based therapeutics to treat cancer. Under this agreement MD Anderson grants exclusive rights to antibodies developed during the... View all Bayer and UCSF Enter into a 10year Research & Development PartnershipBayer and University of California, San Francisco (UCSF) have signed a 10year master research and development agreement. The agreement provides a broad template for collaboration between the two groups around common areas of research interest... View all Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all |
No EVENTS for listing |
No Job Posts |
